SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie, Paris, France.
INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Research Center, Institut Curie, Paris, France.
Int J Cancer. 2019 Jan 1;144(1):68-79. doi: 10.1002/ijc.31620. Epub 2018 Oct 26.
Circulating tumor DNA (ctDNA) is a powerful tool for the molecular characterization of cancer. The most frequent pediatric kidney tumors (KT) are Wilms' tumors (WT), but other diagnoses may occur. According to the SIOP strategy, in most countries pediatric KT have a presumptive diagnosis of WT if they are clinically and radiologically compatible. The histologic confirmation is established after post-chemotherapy nephrectomy. Thus, there is a risk for a small fraction of patients to receive neoadjuvant chemotherapy that is not adapted to the disease. The aim of this work is to perform molecular diagnosis of pediatric KT by tumor genetic characterization based on the analysis of ctDNA. We analyzed ctDNA extracted from plasma samples of 18 pediatric patients with KT by whole-exome sequencing and compared the results to their matched tumor and germline DNA. Copy number alterations (CNAs) and single nucleotide variations (SNVs) were analyzed. We were able to detect tumor cell specific genetic alterations-CNAs, SNVs or both-in ctDNA in all patients except in one (for whom the plasma sample was obtained long after nephrectomy). These results open the door to new applications for the study of ctDNA with regards to the molecular diagnosis of KT, with a possibility of its usefulness for adapting the treatment early after diagnosis, but also for disease monitoring and follow up.
循环肿瘤 DNA(ctDNA)是用于癌症分子特征分析的强大工具。最常见的儿科肾脏肿瘤(KT)是肾母细胞瘤(WT),但也可能有其他诊断。根据 SIOP 策略,在大多数国家,如果儿科 KT 在临床和影像学上与 WT 相符,通常会假定为 WT 进行治疗。在化疗后进行肾切除术以明确组织学诊断。因此,一小部分患者可能会接受不适合疾病的新辅助化疗。本研究旨在通过基于 ctDNA 分析的肿瘤遗传特征对儿科 KT 进行分子诊断。我们通过全外显子组测序分析了来自 18 名儿科 KT 患者的血浆样本中的 ctDNA,并将结果与匹配的肿瘤和种系 DNA 进行比较。分析了拷贝数改变(CNAs)和单核苷酸变异(SNVs)。除了一名患者(其血浆样本是在肾切除术后很久采集的)外,我们能够在所有患者的 ctDNA 中检测到肿瘤细胞特异性遗传改变——CNA、SNV 或两者兼而有之。这些结果为研究 ctDNA 用于 KT 的分子诊断开辟了新的应用途径,有可能在诊断后早期对治疗进行调整,也有可能用于疾病监测和随访。